Immune System Effects in Children Born to Women With Multiple Sclerosis Treated With Monoclonal Antibody Therapy During Pregnancy

Launched by REGION STOCKHOLM ·

Keywords

ClinConnect Summary

This study is looking at how certain medicines given to women with multiple sclerosis (MS) before or during pregnancy might affect their babies’ immune systems. Specifically, it focuses on treatments called monoclonal CD20 antibodies, like rituximab. Researchers want to find out if these medicines change the baby’s immune cells, make them more likely to get infections, or affect how well vaccines work. They also want to see how long the medicine stays in the mother’s body if she received treatment within a year before getting pregnant.

Women with MS who are planning pregnancy or are pregnant and have been treated with these medicines may be able to join. During pregnancy, the mother will give a few extra blood samples during her regular check-ups. After the baby is born, the child will have a blood test within the first year to check their immune responses to vaccines and infections. The study team will also ask the mother about any infections she or her baby might have had. This study is not yet recruiting participants but will help doctors understand the safety of these MS treatments during pregnancy.

Gender

FEMALE

Eligibility criteria